Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Otsuka, Click ‘Digital Therapeutic’ Alliance Aims At Novel Depression Option

Executive Summary

The new alliance is focused on developing a "digital therapeutic" for the treatment of depression. They hope it will take its place as an effective option among current drug and other cognitive therapies.

You may also be interested in...



Otsuka Rescues Fallen Digital Health Unicorn Proteus

Japanese pharmaceutical company picks up struggling US venture for a fraction of its one-time value as it continues strategic push into the digital health space.

Cipla Backs Start-Up As It Builds Digital Health Strategy

Cipla has picked up a minority holding in the Indian digital therapeutics firm Wellthy, and the duo will combine forces to improve patient outcomes in specific chronic therapies.

Bringing A Digital Pill To Oncology: Proteus Partners With Health System To Prescribe Sensor-Enabled Chemotherapy

Proteus Digital Health announced a new partnership with Fairview Health Services and the University of Minnesota Health to prescribe capecitabine, a common chemotherapy drug, encapsulated with a sensor to colorectal cancer patients. Under the program, patients are prescribed the "digital capecitabine" and will be monitored remotely to see when they take their meds and for other health data. The goal is to improve patients' treatment adherence and improve outcomes.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT124512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel